Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.
A large analysis of weight-loss drugs like Ozempic and Wegovy has surprised health researchers, who found links to multiple new benefits – and some new side effects.
Weight-loss jabs could reduce your risk of drug abuse, seizures and pneumonia, as well as heart attacks and strokes, ...
The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback